Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 16, 2018
Inspire Medical Systems, Inc. to Report Third Quarter 2018 Financial Results November 6, 2018
MINNEAPOLIS, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (“Inspire”) (INSP), a medical technology company focused on the development and commercialization of innovative ...
October 16, 2018
Athenex to Present Positive Data of Oraxol Clinical Trial in Breast Cancer at the ESMO 2018 Congress
BUFFALO, N.Y., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for ...
October 16, 2018
Zosano Appoints New Chief Financial Officer
FREMONT, Calif., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver ...
October 16, 2018
Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi ...
October 15, 2018
Genkyotex Announces Presentation of GKT831 Efficacy Data in a Preclinical Model of Advanced Cholestatic Liver Disease at AASLD Liver Meeting® 2018
Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced that an abstract with preclinical data ...
October 15, 2018
Santhera Receives Positive Opinion for Orphan Drug Designation in the EU for POL6014 in Cystic Fibrosis
Pratteln, Switzerland, October 15, 2018 - Santhera Pharmaceuticals (SANN.SW) announces that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued ...
October 15, 2018
Orphazyme endorses patient advocacy consensus guidelines, highlights importance of collaboration with patient communities
Copenhagen, October 15, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced the company’s endorsement of ...
October 15, 2018
Athenex and Xiangxue Life Sciences Announce Preliminary Results of Patients Receiving T-Cell Receptor Affinity Enhancing Specific T-Cell Therapy (TAEST) Showed Encouraging Positive Clinical Signals
BUFFALO, N.Y., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for ...
October 15, 2018
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-ANG3, an RNAi-based ...
October 15, 2018
Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103
PITTSBURGH, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering ...
October 15, 2018
Mustang Bio Appoints Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies based on proprietary ...
October 15, 2018
Tyme Appoints Former Kite and Celgene Executive, Michele Korfin, as Chief Commercial Officer
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies Inc, (TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, ...
October 15, 2018
Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients
Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron ...
October 15, 2018
Albireo Announces Research on Cholestatic Liver Diseases to be Presented at Major North American Liver Meetings
BOSTON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...
October 15, 2018
Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
Sarepta Therapeutics, Inc. (SRPT), a leader in precision genetic medicine for rare diseases, announced today it has signed a license agreement with Lysogene (LYS.PA) (FR0013233475 ...
October 11, 2018
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi® in Combination with Nivolumab in Pancreatic Cancer
NANTES, France, Oct. 10, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA(ISIN: FR0012127173; Mnémo: OSE) today announced the submission of an Investigational New Drug (IND) application ...
October 11, 2018
Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018
Transgene (TNG.PA), a biotech company that designs and develops virus-based immunotherapies, announces that the detailed results of the Phase 1b clinical trial using TG1050 confirm ...
October 11, 2018
Veloxis to Present at Jefferies 2018 London Healthcare Conference
Veloxis Pharmaceuticals A/S (VELO.CO) announced today that CEO Craig Collard will present at the Jefferies 2018 London Healthcare Conference at 8:00 AM GMT on Thursday, November ...
October 11, 2018
Data Presented at ECTRIMS 2018 Show Potential of MOSPD2 as a Novel Target for Treatment of CNS Inflammation, Such as Multiple Sclerosis
TEL AVIV, Israel, Oct. 11, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), announced today that a study entitled “MOSPD2: A Novel Therapeutic Target for ...
October 11, 2018
iCAD Announces Exceptional Study Results Demonstrating Significant Advantages of Revolutionary Artificial Intelligence Technology for Digital Breast Tomosynthesis
NASHUA, N.H. and ATHENS, Greece, Oct. 11, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc.(ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today ...
Page 33 of 138